Clinical trial
CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An…
NCT00479739 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00479739 |
|---|---|
| Title | CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca. |
| Official title | Randomised, Double-blind, Double-dummy, 52-week, Parallel Group Study of a Standard Dosing Regimen With Salmeterol/Fluticasone propionate50/250 Twice Daily Diskus Versus a Symptom-driven, Variable Dosing Regimen With Formoterol/Budesonide Combination 4.5/160 in Adult Asthmatics |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Salmeterol/fluticasone propionate or formoterol/budesonide |
| Enrollment | 700 |
| Start date | Nov 1, 2002 |
| Primary completion | Jul 1, 2004 |
| Completion | Jul 1, 2004 |
| First posted | May 28, 2007 |
| Last update posted | Sep 15, 2016 |
| Countries | Australia, Austria, Belgium, Bulgaria, Canada, Estonia, Finland, Germany, Ireland, Latvia, Netherlands, New Zealand and 3 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: